Valentis (VLTS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Valentis (VLTS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (44)	4/12/2001 9:40:34 AM
From: tuck	Read Replies (1) of 81

>>Valentis Licenses GeneSwitch(TM) Technology to GlaxoSmithKline for Functional Genomics Research BURLINGAME, Calif., April 12 /PRNewswire/ -- Valentis, Inc. (Nasdaq:VLTS - news) today announced that it has granted a non-exclusive license of the Company's GeneSwitch(TM) gene regulation technology to GlaxoSmithKline (NYSE: GSK - news) for use in functional genomics research. The non-exclusive license is for research purposes only, and no financial terms were disclosed. Valentis maintains all rights to clinical gene therapy applications of the GeneSwitch(TM) technology. The GeneSwitch(TM) system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, aiding in the identification and characterization of a gene's function. Valentis is currently developing the GeneSwitch(TM) system as a component of a regulated erythropoietin gene medicine that is expected to begin clinical testing next year. ``The license to GlaxoSmithKline represents the second commercial license of the GeneSwitch(TM) technology to pharmaceutical companies for their internal commercial research efforts that we have completed this year,'' stated Gregory M. McKee, Valentis' Senior Director of Business Development. ``We have also made the GeneSwitch(TM) system available to the academic research community through a license to Invitrogen Corp. (Nasdaq: IVGN - news), and expect to conclude a number of similar licenses over the next year. We believe the GeneSwitch(TM) technology will accelerate the throughput of genomics research because it has the unique ability to completely control gene expression and assist in the identification and characterization of the function of selected genes.''<< snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next